Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Top Cited Papers
Open Access
- 30 March 2017
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 129 (13), 1753-1762
- https://doi.org/10.1182/blood-2016-06-724500
Abstract
An international expert panel, active within the European Society for Blood and Marrow Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Disease risks scored according to the revised International Prognostic Scoring System (IPSS-R) and presence of comorbidity graded according to the HCT Comorbidity Index (HCT-CI) were recognized as relevant clinical variables for HSCT eligibility. Fit patients with higher-risk IPSS-R and those with lower-risk IPSS-R with poor-risk genetic features, profound cytopenias, and high transfusion burden are candidates for HSCT. Patients with a very high MDS transplantation risk score, based on combination of advanced age, high HCT-CI, very poor-risk cytogenetic and molecular features, and high IPSS-R score have a low chance of cure with standard HSCT and consideration should be given to treating these patients in investigational studies. Cytoreductive therapy prior to HSCT is advised for patients with ≥10% bone marrow myeloblasts. Evidence from prospective randomized clinical trials does not provide support for specific recommendations on the optimal high intensity conditioning regimen. For patients with contraindications to high-intensity preparative regimens, reduced intensity conditioning should be considered. Optimal timing of HSCT requires careful evaluation of the available effective nontransplant strategies. Prophylactic donor lymphocyte infusion (DLI) strategies are recommended in patients at high risk of relapse after HSCT. Immune modulation by DLI strategies or second HSCT is advised if relapse occurs beyond 6 months after HSCT.Keywords
This publication has 121 references indexed in Scilit:
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetBlood, 2013
- Hematopoietic SCT in Europe: data and trends in 2011Bone Marrow Transplantation, 2013
- Does iron overload really matter in stem cell transplantation?American Journal of Hematology, 2012
- Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDSBone Marrow Transplantation, 2012
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trialLeukemia, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesThe New England Journal of Medicine, 2011
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinBlood, 2011
- Unraveling the Molecular Pathophysiology of Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemiaBlood, 2010
- Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersBlood, 2007